Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2019 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMPHASTAR PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware (State or other juri ...

Company Overview - Amphastar is a specialty pharmaceutical company focused on technically challenging generic and proprietary injectable and inhalation products[31] - The company is vertically integrated from R&D to clinical trials, manufacturing, marketing and distribution[6] - The company has over 2,000 employees and 1.9 million square feet of facilities[6] Financial Performance - The company had approximately $295 million in revenue in 2018[31] - The company had approximately $107 million in gross profit in 2018[31] - Enoxaparin sales were approximately $53 million in 2018[6] Pipeline and R&D - The company has a robust pipeline of over 20 product candidates in attractive markets[31] - The company has 290 employees dedicated to R&D[7, 12] - The company has four filed ANDAs with IQVIA sales of approximately $800 million[13] - The company has five injectable ANDAs in development targeting products with IQVIA sales of approximately $4 billion[13] - The company has six inhalation ANDAs in development targeting products with IQVIA sales of approximately $10 billion[13] - The company has injectable biosimilars in development targeting products with IQVIA sales of approximately $14 billion[14]

Table of Contents | --- | --- | |--------------------------------------------------------------------------|-------------| | | | | UNITED STATES SECURITIES AND EXCHANGE Washington, D.C. 20549 | COMMISSION | | | FORM 10-Q | ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2019 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 ...

| --- | --- | |-------|---------------------------------------------------------------------------------| | | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | FORM 10-K | ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ | --- | --- | --- | --- | --- | --- | |--- ...